Table 4.

Analyses of progression-free survival (chemotherapy recipients)

	Univariate			Multivariate
	RR	95% CI	P-value	RR	95% CI	P-value
Age (≤70 yrs)	2.83	1.05–9.05	.04	3.90	1.38–13.1	<.01
Gender (male)	1.43	0.58–4.06	.45
Tumor site (head)	0.90	0.36–2.14	.81
Tumor size (≥30 mm)	1.37	0.57–3.62	.50
Stage IV (UICC)	2.30	0.95–5.76	.06	4.00	1.44–12.2	<.01
CEA (≥5 ng/mL)	1.49	0.63–3.48	.36
CA19-9 (≥37 mAU/mL)	1.81	0.74–5.10	.20	1.93	0.78–5.48	.16
Plasma KRAS mutation	0.63	0.22–1.57	.34	0.51	0.17–1.33	.17

CEA, carcinoembryonic antigen; RR, relative risk; UICC, Union for International Cancer Control.